| Lincoln Behavioral Health Clinic, Inc. | |
|
1715 26th St Central City NE 68826-9501 | |
| (402) 489-9959 | |
| (402) 489-2219 |
| Full Name | Lincoln Behavioral Health Clinic, Inc. |
|---|---|
| Speciality | Psychologist |
| Location | 1715 26th St, Central City, Nebraska |
| Authorized Official Name and Position | Judy E Byrns (OWNER) |
| Authorized Official Contact | 4024899959 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Lincoln Behavioral Health Clinic, Inc. 3201 Pioneers Blvd Suite 202 Lincoln NE 68502-5963 Ph: (402) 489-9959 | Lincoln Behavioral Health Clinic, Inc. 1715 26th St Central City NE 68826-9501 Ph: (402) 489-9959 |
| NPI Number | 1073604799 |
|---|---|
| Provider Enumeration Date | 09/27/2006 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073604799 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Primary |
News Archive
If you're serious about losing weight, check out recent studies done in Elvira de Mejia's University of Illinois laboratory. Her research provides insight into the way a certain type of soy protein inhibits fat accumulation and reduces inflammation.
Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under a licensing agreement related to its U.S. Patent No. 6,531,276 (the "276 Patent").
Altus Pharmaceuticals Inc. (Nasdaq: ALTU) today announced that on September 15, 2009, the Company received a letter from the Nasdaq Listing Qualifications Department notifying the Company that, for the last 30 consecutive business days, the bid price of the Company's common stock has closed below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company's shares will continue to trade on the Nasdaq Capital Market under the symbol "ALTU."
Despite reports that children and young people may be less likely to get coronavirus disease 2019 (COVID-19) than older adults, there may be substantial indirect adverse effects of the disease on their physical and mental health, according to an analysis in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago